NICE National Institute for Health and Care Excellence



Etrasimod for treating moderately to severely active ulcerative colitis in people aged 16 and over

Information for the public Published: 11 March 2024

www.nice.org.uk

Etrasimod (Velsipity) is available on the NHS. It is a possible treatment for moderately to severely active ulcerative colitis in people aged 16 and over if conventional treatments (such as aminosalicylates or corticosteroids) or biological treatments (such as adalimumab, golimumab, infliximab, ustekinumab or vedolizumab) are not tolerated, or have not worked well enough.

Is this treatment right for me?

Your healthcare professionals should give you clear information, talk with you about your options and listen carefully to your views and concerns. Your family can be involved too, if you wish. See <u>our webpage on making decisions about your care</u>.

Etrasimod for treating moderately to severely active ulcerative colitis in people aged 16 and over

Questions to think about

- How well does it work compared with other treatments?
- What are the risks or side effects? How likely are they?
- How will the treatment affect my day-to-day life?
- What happens if the treatment does not work?
- What happens if I do not want to have treatment? Are there other treatments available?

Information and support

The <u>NHS webpage on ulcerative colitis</u> may be a good place to find out more.

Crohn's and Colitis UK, 0300 222 5700, can give you advice and support.

You can also get support from your local <u>Healthwatch</u>.

NICE is not responsible for the quality or accuracy of any information or advice provided by these organisations.

ISBN: 978-1-4731-5748-4